The PDGFR prototype inhibitor, imatinib, which also inhibits c-kit and c-Abl, has become the standard treatment for chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST) with excellent results. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.